Professor Jonathan Williams, one of the UK’s leading organic chemists, has received a Royal Society Wolfson Merit Award for his research.
Williams, from the University of Bath’s Department of Chemistry, is the recipient of a £10,000 a year award over a five-year period. The award will fund his research group’s work in designing metal catalysts for new chemical reactions.
In many cases, the metal catalysts developed by the group allow reactions to be more environmentally friendly because molecules can be constructed more efficiently and use less energy.
Professor Paul Raithby, Head of the Department of Chemistry, said: ‘Jonathan is undoubtedly one of the most creative and productive organic chemists of his generation in the UK. His work has influenced academic chemistry internationally, as well as having had significant impact in industrial practice.
‘Jonathan has attracted a talented group of organic chemists to Bath and we are determined to support him in further developing the department’s international reputation as a leading centre for catalysis and chemical synthesis. This award is a significant contribution to that goal.’
Until recently, the research group worked on a method of constructing chemical bonds using catalytic reactions that they termed ‘Borrowing Hydrogen Methodology’. This focused on the metal catalyst temporarily removing hydrogen from the starting material, allowing it to react more easily.
Williams said: ‘The resulting compounds from this technique are made more cleanly than they would be traditionally. Using our methodology, the only by-product created is water, and there is no need to use carcinogenic starting materials.’
The group has since changed its focus and the Wolfson Merit Award will fund research into new catalytic reactions.
‘We’re now focusing on developing new approaches to the formation of amides, the chemical bonds found in proteins, in many drug molecules, and in robust materials such as Nylon and Kevlar,’ said Williams.
‘This new research will aim to identify catalytic methods for the formation of amides, which are traditionally prepared using cumbersome, inefficient chemistry.’
Bath professor receives Wolfson Merit Award
The award will fund Jonathan Williams\' research into metal catalysts for new chemical reactions
You may also like
Research & Development
OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial
OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development
Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss
Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory
Johnson & Johnson files FDA application for IMAAVY in wAIHA
Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development
Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies
Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Research & Development
SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration
A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Landmark NHS‑Galleri trial cuts Stage IV cancers and boosts early detection across England
NHS‑Galleri trial shows multi‑cancer blood test sharply reduces late‑stage diagnoses and boosts early detection—possibly signalling a structural change in cancer drug demand, supply chain planning and long-term oncology production strategy